SCHEMBL508777

SCHEMBL508777

COc1cc2cc(-c3cccc(C)c3)nc(N)c2cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.55
RAC1 P63000 4/20 0.51
KDM4E B2RXH2 6/20 0.50
MAPT P10636 3/20 0.50
TP53 P04637 2/20 0.49
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
DHPS P49366 2/20 0.47
PDPK1 O15530 1/20 0.46
ALDH1A1 P00352 4/20 0.46
XDH P47989 1/20 0.45
HSD17B10 Q99714 3/20 0.44
TSHR P16473 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509022 0.86 RAD52 (0.52) RAD52RAC1KDM4EMAPTRAB9A
SCHEMBL13076486 0.86 RAC1 (0.68) RAC1KDM4EMAPTTP53RAB9A
SCHEMBL510224 0.85 SMN1; SMN2 (0.58) RAD52RAC1KDM4EMAPTRAB9A
SCHEMBL12070505 0.82 RAD52 (0.53) RAD52RAC1KDM4EMAPTRAB9A
SCHEMBL509287 0.81 RAD52 (0.59) RAD52RAC1KDM4EMAPTTP53
SCHEMBL509539 0.81 XDH (0.50) KDM4ERAB9ANPC1MEN1KMT2A
SCHEMBL509097 0.81 XDH (0.50) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL509771 0.78 KDM4E (0.52) RAD52RAC1KDM4EMAPTTP53
SCHEMBL3321563 0.78 RAC1 (0.65) RAD52RAC1KDM4EMAPTRAB9A
SCHEMBL510204 0.78 RAD52 (0.49) RAD52RAC1KDM4EMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 RAD52 542/4885RAC1 2236/4885KDM4E 2109/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 RAD52 542/4885RAC1 2236/4885KDM4E 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.